US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, and biotechnology company Moderna Inc (Nasdaq:MRNA) announced on Monday that they have initiated the INTerpath-009 Phase 3 clinical trial evaluating the investigational individualised neoantigen therapy, V940 (mRNA-4157), in combination with KEYTRUDA (pembrolizumab) for early-stage non-small cell lung cancer (NSCLC) patients.
This trial will assess the combination therapy's impact on disease-free survival, overall survival and other key measures in patients who have received neoadjuvant KEYTRUDA and chemotherapy.
A global, randomised, double-blind Phase 3 trial, INTerpath-009 will evaluate 680 patients with resected (R0 or R1) Stage II, IIIA, IIIB (N2) NSCLC who did not achieve a pathological complete response (pCR) after neoadjuvant KEYTRUDA plus platinum-based chemotherapy.
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Biond Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
GlycoMimetics to combine with Crescent Biopharma
MilliporeSigma expands ADC manufacturing capacity
Merck and Moderna launch new Phase 3 trial for cancer vaccine
RaySearch Laboratories AB names new CFO
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
Elicera Therapeutics completes patient enrolment for phase I/II trial of cancer therapy ELC-100
Repare Therapeutics reports positive safety and tolerability data from Phase 1 MYTHIC trial